Psoriatic Arthritis | Current Treatment | EU5 | 2017
Following the European Medicines Agency’s approvals of the PDE-4 inhibitor Otezla and the IL-17 inhibitor Cosentyx for psoriatic arthritis (PsA), treatment of this disease in the EU5 has begun to move away from its heavy reliance on TNF inhibitors. Both IL-17 inhibition and PDE-4 antagonism are new mechanisms of action for rheumatologists. Their early perceptions of these two agents can shed light on the long-term commercial prospects for the two drug classes. Also affecting the PsA therapy market in the EU5 are the launches of biosimilar etanercept and biosimilar infliximab, both of which will further reduce the uptake of the brand TNF inhibitors and may affect use of later-line therapies. These two dynamic forces are poised to reshape the treatment algorithm for PsA.
Questions Answered:
What are the latest trends in diagnosis and treatment rates for PsA in the EU5?
How do dermatologists collaborate with rheumatologists in the treatment of PsA in each EU5 country?
What are the current and rheumatologist-predicted future DMARD utilizations in the PsA therapy market?
What are rheumatologists’ rationales behind therapy switches and therapy discontinuation?
What are rheumatologists’ perceptions of and prescribing behaviors for Benepali and Inflectra in the EU5?
Where do Cosentyx and Otezla fit into European rheumatologists’ treatment algorithms?
Scope:
Markets covered: France, Germany, Italy, Spain, and the United Kingdom.
Indication coverage: Psoriatic arthritis
Methodology: Surveys of 250 rheumatologists (50 in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom) completed in February 2017.